abstract: Pregnancies complicated by pre-eclampsia and small-for-gestational-age (SGA) infants demonstrate impaired placental vascular remodelling. Angiopoietin-1 (ANG-1) is an angiogenic growth factor which regulates vascular integrity and remodelling. The TT genotype of angiopoietin 1 (ANGPT1) rs2507800 polymorphism has been associated with increased plasma ANG-1 levels compared with the AA genotype. We aimed to investigate the association between ANGPT1 rs2507800 polymorphism and pregnancies complicated by gestational hypertensive disorders and SGA infants. We also aimed to investigate whether the polymorphism was associated with abnormal uterine artery Doppler as a surrogate marker of impaired placental vascular remodelling. Genotyping data of 1361 nulliparous pregnant women, 1226 partners and 1190 infants were analysed. The prevalence of ANGPT1 rs2507800 TT genotype was reduced in women with pre-eclampsia [P ¼ 0.01, adjusted odds ratio (aOR), 0.5; 95% confidence interval (CI), 0.3 -0.9], hypertensive SGA (P ¼ 0.04, aOR, 0.5; 95% CI, 0.2-0.9) and SGA with abnormal uterine artery Doppler (P ¼ 0.009, aOR, 0.4. 95% CI, 0.2-0.8) compared with women with uncomplicated pregnancy. The prevalence of maternal ANGPT1 rs2507800 TT genotype was reduced in women with increased uterine artery resistance index (P ¼ 0.03, aOR, 0.7; 95% CI, 0.5 -0.9) and bilateral notching of the uterine arteries (P ¼ 0.004, aOR, 0.6; 95% CI, 0.4 -0.9). These results remained significant after correcting for multiple testing. Maternal ANGPT1 rs2507800 TT genotype is associated with a reduced risk for pre-eclampsia, hypertensive SGA and abnormal uterine artery Doppler. These findings suggest that the TT genotype may protect against these pregnancy disorders by increasing ANG-1 production at the maternal -fetal interface. The ANGPT1 rs2507800 polymorphism may have a potential role in screening women to predict the risk of these pregnancy complications.
Introduction
Pre-eclampsia, gestational hypertension and small-for-gestational-age (SGA) infants complicate 15-20% of all nulliparous pregnancies (Sibai et al., 2005; Hutcheon et al., 2011) . Women who develop preeclampsia or deliver SGA infants are at increased risk for later life vascular disorders including coronary artery disease and stroke (McDonald et al., 2008) .
The cause of these pregnancy complications remains largely unknown but impaired maternal spiral artery remodelling is implicated in the pathogenesis of pre-eclampsia and SGA pregnancies (Khong et al., 1986; Mayhew et al., 2004) . These abnormalities result in increased vascular impedance in the uterine circulation which is detected as an increased uterine artery resistance index (RI) on Doppler velocimetry (Chen et al., 2002; Deurloo et al., 2009) .
Many molecular pathways are involved in the regulation of maternal spiral artery remodelling, of which the angiopoietin family-mediated angiogenic pathway is recognized as playing a key role (Geva et al., 2002) . During pregnancy, angiopoietin-1 (ANG-1) and its receptor Tie-2 are expressed in many cells at the maternal-fetal interface (Seval et al., 2008; Schiessl et al., 2009) . Angiopoietin 1 (ANGPT1) gene ablation in mice results in severe angiogenic defects and embryonic lethality further, demonstrating that ANGPT1 has a critical role in embryonic angiogenesis (Suri et al., 1996) .
A single-nucleotide polymorphism (SNP) located in the microRNA-211 (miRNA-211) target site in the 3 ′ untranslated region of ANGPT1 is found in 58% of Caucasian populations (ANGPT1 rs2507800, National Center for Biotechnology Information db SNP database). The A allele is known to suppress ANG-1 translation by facilitating miRNA-211 binding, while the T allele is resistant to miRNA-211 induced reduction in translation. The TT genotype is also associated with higher plasma ANG-1 levels compared with the AA genotype (Chen et al., 2010) . The TT genotype was recently shown to be associated with a reduced risk of stroke in two independent large cohorts (Chen et al., 2010) .
Considering the role of ANG-1 in placental vascular remodelling, the consistent association of ANGPT1 rs2507800 polymorphism with stroke and the data showing that women who develop pre-eclampsia or deliver SGA infants are at a higher risk of stroke, we aimed to investigate the association between the ANGPT1 rs2507800 polymorphism and pregnancies complicated by pre-eclampsia, gestational hypertension and SGA infants. We also aimed to investigate the association of this polymorphism with abnormal uterine artery Doppler as a surrogate marker of impaired spiral artery remodelling.
Materials and Methods

Study population
We conducted a nested case -control study where participants were recruited from the SCOPE (screening for pregnancy end-points) study. The SCOPE study is an international, multicentre, prospective cohort study with the aim of developing screening tests to predict pre-eclampsia, SGA infants and preterm birth across different populations. Ethics approval was obtained from local ethics committees, and all participants provided written informed consent.
Nulliparous women with singleton pregnancies were recruited between November 2004 and September 2008 in Adelaide, Australia, and Auckland, New Zealand. Women considered at high risk of pre-eclampsia, SGA infants or preterm birth because of underlying medical, obstetric or gynaecological conditions were not eligible (Andraweera et al., 2011) . Women were interviewed and examined by a research midwife at 15 + 1 and 20 + 1 weeks of gestation. Maternal data on demographics, medical history, previous obstetric history, family history of obstetric and medical disorders as well as current pregnancy data on any complications during pregnancy, diet, smoking, alcohol and the use of recreational drugs were collected. Maternal height, weight and blood pressure were measured at 15 weeks of gestation. Proteinuria in a mid-stream urine specimen was measured by dipstick or a protein:creatinine ratio.
If the woman was certain of the identity of the infant's father, the father was invited to participate in the study. Consenting male participants were interviewed at either the 15 + 1 or 20 + 1 weeks' visit. Paternal data collected included age, ethnicity and birthweight. Paternal height and weight were also measured.
All women were followed prospectively, and Doppler ultrasound of the uterine arteries was performed at 20 weeks of gestation (Groom et al., 2009) . Mean uterine artery RI was calculated from the left and right uterine RI. Notching of each uterine artery was also recorded. A mean uterine artery RI .90th centile was considered abnormal. Pregnancy outcome data and measurements of the infant were recorded within 72 h of birth.
The primary outcomes were 'gestational hypertension' defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg on two or more measurements 6 h apart after 20 weeks of gestation but before the onset of labour; 'pre-eclampsia' defined as gestational hypertension or post-partum hypertension with proteinuria (24-h urinary protein .300 mg or spot urine protein:creatinine ratio ≥30 mg/mmol creatinine or urine dipstick protein ≥++) or any multisystem complication of pre-eclampsia ; SGA defined as a birthweight ,10th customized centile adjusted for maternal height, weight, parity and ethnicity, as well as gestational age at delivery and infant sex (McCowan et al., 2004) ; 'normotensive SGA', defined as birth of an SGA infant where the mother did not have hypertension; 'hypertensive SGA', defined as birth of an SGA infant where the mother had either gestational hypertension or pre-eclampsia, 'SGA' with abnormal Doppler defined as SGA with mean uterine artery RI .90th centile. 'Uncomplicated pregnancy' was defined as a pregnancy with no antenatal medical or obstetric complications and resulting in the delivery of an appropriately grown, healthy infant at ≥37 weeks of gestation.
Peripheral blood samples were collected from the women. Peripheral blood, buccal sawbs or saliva samples were collected from partners. Cord blood, buccal swabs or saliva samples were collected from infants. The buccal swabs were applied to Whatman FTA cards (Whatman, Inc., Piscataway, NJ, USA) immediately following sample collection, and saliva was collected using Oragene Kit (DNA Genotek, Inc., Kanata, Ont., Canada).
Genotyping
DNA was extracted from buffy coats from peripheral or cord blood, Whatman FTA cards or from saliva (Oragene w DNA Kit) according to the manufacturers' instructions. Genotyping for the ANGPT1 rs2507800 polymorphism was performed at the Australian Genome Research Facility (AGRF) using the Sequenom MassARRAY system. The primer sequences were as follows: first PCR primer, 5
′ -ACGTTGGATGGGGAGAAAAA TTGGCAAAAC-3 ′ ; second PCR primer, 5 ′ -ACGTTGGATGTTCTTAGT CAGGTGACTATG-3 ′ and extension primer, 5 ′ -GCAAAACTATTATA TGTAAGGGA-3 ′ . As a quality-control measure, each sample was also genotyped for Amelogenin to ensure that the sex of the sample was correct (Sullivan et al., 1993) .
Statistics
Women, partners and infants in the adverse pregnancy outcome group (cases) were compared with women, partners and infants in the uncomplicated pregnancy group (control subjects) in a nested case-control study design. Missing data were excluded from the analyses. The x adjusted for previously established risk factors (McCowan et al., 2010 North et al., 2011) . A false discovery rate (FDR) correction was performed to adjust for multiple comparisons controlling the FDR at 15% (Benjamini et al., 2001) . All data analyses were performed using PASW, version 17.02 (SPSS, Inc., Cary, NC, USA). Results were reported as number and percent [n (%)] or mean + standard deviation where appropriate. P , 0.05 was considered statistically significant.
Results
After the exclusion criteria detailed in Fig. 1 (and excluding patients with 'other complications'), genotyping data of 1361 women, 1226 partners and 1190 infants were analysed. Maternal and paternal characteristics, Doppler results and pregnancy outcome data in relation to adverse pregnancy outcomes are detailed in Table I . The ANGPT1 rs2507800 polymorphism showed no deviation from the Hardy -Weinberg equilibrium. The TT genotype of the maternal ANGPT1 rs2507800 polymorphism was associated with a reduced risk for pre-eclampsia [aOR, 0.5; 95% confidence interval (CI), 0.3 -0.9; P ¼ 0.01, recessive model; Table II ], hypertensive SGA (aOR, 0.5; 95% CI, 0.2-0.9; P ¼ 0.04, recessive model; Table II ) and SGA with abnormal Doppler (aOR, 0.4; 95% CI, 0.2 -0.8; P ¼ 0.009, dominant model, Table II ). Maternal ANGPT1 rs2507800 was not associated with gestational hypertension or with normotensive SGA (P . 0.05, Table II ). Paternal and neonatal ANGPT1 rs2507800 were not associated with any of the adverse pregnancy outcomes (data not presented).
The maternal ANGPT1 rs2507800 TT genotype was also associated with a higher infant birthweight which was adjusted for gestational age at delivery and maternal smoking at 15 weeks of gestation (P ¼ 0.03, recessive model, Fig. 2) .
The maternal ANGPT1 rs2507800 TT genotype was associated with a reduced risk for abnormal uterine artery Doppler (OR, 0.7; Figure 1 Study population. NSGA, normotensive small for gestational age; GH, gestational hypertension.
ANGPT1 polymorphism in pregnancy complications 95% CI, 0.5 -0.9; P ¼ 0.03, dominant model; Table III ) and bilateral notching of the uterine artery waveform (OR, 0.6; 95% CI, 0.4-0.9; P ¼ 0.004, dominant model; Table III ). When adjusted for maternal smoking at 15 weeks of gestation, the results remained unchanged (Table III) . All results remained significant after correcting for multiple testing.
Discussion
To our knowledge, this is the first study to investigate the ANGPT1 rs2507800 polymorphism in pregnancy complications. Our study demonstrates that the maternal ANGPT1 rs2507800 TT genotype is associated with a reduced risk for pre-eclampsia, hypertensive SGA and SGA with abnormal uterine artery Doppler. The maternal ANGPT1 rs2507800 TT genotype is also associated with a reduced risk for abnormal uterine artery Doppler.
Impaired maternal spiral artery remodelling is implicated in the pathogenesis of the aforementioned pregnancy complications (Khong et al., 1986) . ANG-1 and its receptor Tie-2 are expressed at the maternal -fetal interface and are of critical importance in placental vascular remodelling (Dunk et al., 2000; Geva et al., 2002; Seval et al., 2008; Schiessl et al., 2009) . The A allele of the ANGPT1 rs2507800 polymorphism is known to suppress ANG-1 translation by facilitating miR-211 binding. The T allele is resistant to miR-211-induced reduction in translation, and subjects carrying the TT genotype have higher plasma ANG-1 levels than those with the AA or AT genotypes (Chen et al., 2010) . We observed that the frequency of the TT genotype was reduced in women who developed pre-eclampsia, hypertensive SGA and SGA with abnormal uterine Doppler. We hypothesize that the TT genotype may contribute to increased ANG-1 production at the maternal -fetal interface.
Consistent with this, we found that the frequency of the TT genotype was reduced in women who had abnormal mean uterine RI as well as in those with bilateral notching of the uterine artery waveform at the 20-week Doppler scan. As smoking is known to influence the expression of angiogenic growth factors and also impacts on uterine artery Doppler indices possibly through this mechanism, we included maternal smoking at 15 weeks of gestation in our logistic regression model (Pons and Marin-Castano, 2011) . The protective effect of ANGPT1 rs2507800 TT genotype was independent of maternal smoking.
We did not find a significant association of the polymorphism with gestational hypertension if not complicated by SGA or normotensive SGA. This is consistent with the theory that utero-placental vascular remodelling is unaffected in gestational hypertension not associated with SGA (Khong and Brosens, 2011) .
A history of pre-eclampsia is associated with increased long-term risk for vascular diseases including coronary artery disease and stroke (McDonald et al., 2008) . The relationship between preeclampsia and later life vascular disease involves shared risk factors for both, including chronic endothelial dysfunction (Chambers et al., 2001; Bushnell and Chireau, 2011) . Furthermore, familial segregation of pre-eclampsia as well as cardiovascular and cerebrovascular disease suggest that these diseases share a common genetic predisposition that interact with the environment and may predispose individuals to vascular disorders which manifest at different time points SGA, small-for-gestational-age infant; T allele %, T allele frequency; additive model 1, AT compared with AA; additive model 2, TT compared with AA; dominant model, AT + TT compared with AA; recessive model, TT compared with AA + AT. aP-value and aOR (95% CI) for pre-eclampsia and gestational hypertension adjusted for maternal factors; maternal age, mean arterial pressure at 15 weeks of gestation, BMI, family history of pre-eclampsia, family history of coronary artery disease, maternal birthweight, vaginal bleeding for at least 5 days during pregnancy, previous single miscarriage with the same partner, taking at least 12 months to conceive, low intake of fruit, cigarette smoking and alcohol use in the first trimester and paternal factors; age and BMI; aP-value and aOR (95% CI) for normotensive SGA, hypertensive SGA and SGA with abnormal Doppler adjusted for maternal factors; age, BMI, birthweight, smoking, low fruit and vegetable intake and paternal BMI and birthweight; bold indicates significant values.
throughout the life course. The TT genotype of ANGPT1 rs2507800 polymorphism which is associated with higher plasma ANG-1 was recently shown to be associated with a significant reduced risk for both haemorrhagic and ischaemic stroke in two large independent cohorts (Chen et al., 2010) . ANG-1 acting through Tie-2 receptor plays a critical role in maintaining the integrity of the vascular endothelium and in suppressing endothelial permeability (Thurston et al., 2000) . The protective effect of the TT genotype of ANGPT1 rs2507800 polymorphism on pre-eclampsia and haemorrhagic stroke suggests that the associations may be due to its contribution in reducing endothelial dysfunction.
The strengths of our study include a large prospective cohort and collection of data on a large number of clinical variables. The clinical variables used in our multivariable logistic regression models were previously shown to be associated with pre-eclampsia and SGA pregnancies in our study cohort (McCowan et al., 2010 North et al., 2011) . Our data show that the association of the maternal ANGPT1 rs2507800 polymorphism with pre-eclampsia, hypertensive SGA and SGA with abnormal Doppler is independent of these clinical risk factors. The availability of uterine artery Doppler ultrasound prior to the development of pregnancy complications also enables us to comment on the potential mechanistic role of the polymorphism in the pathogenesis of these pregnancy disorders.
We acknowledge the following limitations in our study. Given the sample size of our cohort and a prevalence of ANGPT1 rs2507800 TT genotype in 36.4% of women in the study cohort with complete genotyping information (n ¼ 1361), the pre-eclampsia, gestational hypertension and normotensive SGA groups had 80% power to detect an OR of 0.5 (b ¼ 80%, a ¼ 0.05) but our groups of hypertensive SGA and SGA with abnormal uterine artery Doppler were relatively small. Hence, replication in other independent cohorts as well as investigating the effects of genotype on plasma ANG-1 during pregnancy will be beneficial.
At present, literature on the predictive role of plasma ANG-1 on pregnancy complications is limited, but it has been shown that the ratio of plasma ANG-1 to ANG-2 is reduced in pre-eclampsia (Bolin et al., 2009) . However, ANG-1 production is regulated by many factors and also the changes are detected only during the latter part of the pregnancy (Bolin et al., 2009; Hindle et al., 2010) , making it an unsuitable marker for screening for pregnancy complications.
Considering the functionality of the polymorphism and the known association with stroke, our results are consistent with previous evidence. If similar genotype associations are demonstrated in a replication cohort, this polymorphism in combination with other clinical risk factors may have a potential role in early screening to predict the risk of these pregnancy complications.
In conclusion, our study demonstrates that the maternal ANGPT1 rs2507800 polymorphism is associated with a reduced risk for preeclampsia, hypertensive SGA and SGA with abnormal uterine artery Doppler and that it may have a protective effect on the pathogenesis of these pregnancy complications.
